CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$61.55 USD
+4.09 (7.12%)
Updated Jul 16, 2024 01:12 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 141 - 160 ( 217 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Partner Vertex Discusses Joint Program in Hemoglobinopathies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Functional Cures Continue to KO Hemoglobinopathies. Raising PT to $170.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Gene-Edited Hemoglobinopathy Therapy Ameliorates Symptoms: ASH Abstrac
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q20 - Regenerative Medicine Program to Move into Clinic in 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department